Most Valued Company Award Presented During Angel Capital Expo State College, PA (October 30, 2017) – INDIGO Biosciences, Inc. is pleased to announce that it was awarded the Stephen M. Goodman Most Valued Company Award at the Keiretsu Forum Angel Capital Expo. The Expo took place October 19, 2017 at the Union League in Philadelphia,Read More
INDIGO Announces Relaunch of Nuclear Receptor Resource Website
Premiere Educational Resource for Human Nuclear Receptor Information State College, PA (12/8/2016) INDIGO Biosciences, Inc. is pleased to announce the relaunch of the Nuclear Receptor Resource website. The NRR is a premier educational resource for information on the 48 human nuclear receptors. The NRR website has undergone a major redesign to make the site easierRead More
INDIGO Biosciences and Bertin Pharma Sign European Distribution Agreement
Ready-to-Use Nuclear Receptor Assay kits for over 20 disease states, including Cardiovascular and Metabolic Disease, Cancer, and Inflammation State College, PA (November 15, 2016) INDIGO Biosciences, the recognized industry-leader in Nuclear Receptor research, and Bertin Pharma have announced the completion of a European distribution agreement. Over 40 product references for studying nuclear receptors are nowRead More
INDIGO Offers Expansion of Industry-Leading FXR Assay
Meets industry demand for increased pre-clinical predictability. State College, PA (August 9, 2016) INDIGO Biosciences, the recognized industry leader in Nuclear Receptor research, announced the addition of the Mouse Farnesoid X Receptor (mFXR) assay to their FXR portfolio. This addition both complements INDIGO’s industry-leading human FXR assay and meets the demand for an expansion ofRead More